Devonian Health Group Announces Closing of the First Tranche of a Private Placement of $2,292,199.50
Devonian Health Group Announces Closing of the First Tranche of a Private Placement of $2,292,199.50
Not for distribution to United States newswire services or for dissemination in the United States
不得分發給美國通訊社或在美國境內傳播
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has closed the first tranche of a non-brokered private placement (the "Offering") by issuing 7,640,665 units (the "Units") at a price of $0.30 per Unit for aggregate gross proceeds of $2,292,199.50. Each Unit consists of one subordinate voting share and one share purchase warrant (a "Warrant"). Each Warrant will entitle its holder to purchase one subordinate voting share, at a price of $0.40, until November 13, 2023.
魁北克市--(美國商業新聞網)--泥盆紀健康集團有限公司(“泥盆紀“或”公司") (TSXV:政府物料供應處),一家專注於開發獨特的植物醫藥和化粧品產品組合的臨牀期植物製藥公司高興地宣佈,它已經完成了第一批非經紀私募。供奉“)發行7,640,665個單位(”單位“),每單位作價0.30美元,總收益為2,292,199.50美元。每個單位包括一個附屬有表決權股份和一個股票認購權證(A)搜查令“)。在2023年11月13日之前,每份認股權證持有人將有權以0.40美元的價格購買一股附屬有表決權股票。
The net proceeds of the Offering will be used by the Corporation for working capital and general corporate purposes.
是次發行所得款項淨額將由該公司用作營運資金及一般公司用途。
Finder's fees totalling $15,132.02 were paid to finders in connection with this Offering. All securities issued under the Offering are subject to a four month and one day hold period from the date of issue in accordance with applicable securities laws, ending on March 13, 2022. This Offering has received conditional approval from the TSX Venture Exchange and remains subject to the final approval of the TSX Venture Exchange.
發現者的費用總額為15,132.02美元,支付給與此次發行相關的發現者。根據此次發行發行的所有證券,根據適用的證券法,自發行之日起有4個月零1天的持有期,截止日期為2022年3月13日。此次發行已獲得多倫多證券交易所的有條件批准,並仍有待多倫多證券交易所風險交易所的最終批准。
Due to high demand from investors for the Units of the Offering, the Corporation announces its intention to close a second tranche of this Offering on or prior to November 26, 2021, for additional aggregate gross proceeds of $3,000,000.
由於投資者對此次發行單位的需求很高,該公司宣佈打算在2021年11月26日或之前完成此次發行的第二批股票發行,總收益總額增加300萬美元。
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
本新聞稿不構成出售或邀請購買美國任何證券的要約。這些證券沒有也不會根據修訂後的《1933年美國證券法》(《美國證券法》)註冊。美國證券法“)或任何州證券法,除非根據美國證券法和適用的州證券法註冊或獲得此類註冊豁免,否則不得在美國境內或向美國人提供或銷售。
About Devonian
關於泥盆紀
Devonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian's flagship product, Thykamine™, the first pharmaceutical product issued from Devonian's SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and in a large phase 2 clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis. The product is now ready to move into phase 3 clinical development.
泥盆紀健康集團公司是一家晚期植物製藥公司,擁有針對未得到滿足的醫療需求的新型治療方法。泥盆紀公司的核心戰略是從植物材料和藻類中開發植物處方藥,用於治療炎症-自身免疫性疾病,包括但不限於潰瘍性結腸炎和特應性皮炎。基於超過15年的研究基礎,泥盆紀公司的重點進一步得到了美國-FDA的一套管理指南的支持,該指南支持處方藥植物藥產品比傳統處方藥更有效的藥物開發途徑。泥盆紀的旗艦產品Thykamine™是從泥盆紀的SUPREX™平臺發行的首個製藥產品,是一種高度創新的產品,用於預防和治療與炎症和氧化應激相關的健康狀況。胸腺胺™的抗炎、抗氧化和免疫調節特性已經在相當多的體外和體內研究以及在輕到中度遠端潰瘍性結腸炎患者的IIa期臨牀試驗和在輕到中度特應性皮炎的成人患者的大型2期臨牀試驗中得到證實。該產品現已準備好進入第三階段臨牀開發。
Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability 'from the seed to the pill'. Acquired in 2018, Altius Healthcare Inc., its commercialization subsidiary, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSXV Exchange (TSXv:GSD).
泥盆紀公司還參與了高價值化粧品的開發,利用與其製藥產品相同的專利方法。泥盆紀健康集團公司成立於2015年,總部設在加拿大魁北克,在那裏它擁有最先進的提取設施,從種子到藥丸都可以完全追溯。其商業化子公司Altius Healthcare Inc.於2018年被收購,為進一步多元化和增長潛力帶來了機遇。泥盆紀在多倫多證券交易所(TSXV)公開交易(TSXV:政府物料供應處).
For more information, visit www.groupedevonian.com
欲瞭解更多信息,請訪問www.groupedevonian.com。
Forward-Looking Statements
前瞻性陳述
This press release contains forward-looking statements about Devonian's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, the intended use of proceeds of the Offering, the final approval of the TSX Venture Exchange in connection with the Offering, the above "About Devonian" paragraph, Devonian's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian's prospectus dated April 21st, 2017 under the heading "Risk Factors" related to Devonian's business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.
本新聞稿包含有關泥盆紀公司的目標、戰略和業務的前瞻性陳述,涉及風險和不確定性。這些陳述是“前瞻性的”,因為它們是基於我們目前對我們所處市場的預期,以及各種估計和假設。如果已知或未知的風險影響我們的業務,或者如果我們的估計或假設被證明是不準確的,實際事件或結果可能與這些前瞻性陳述中預期的大不相同。這些風險和假設包括,但不限於,此次發行所得的預期用途,多倫多證券交易所與此次發行相關的最終批准,上述“關於泥盆紀”段落,泥盆紀公司開發、製造和成功商業化增值藥品和化粧品的能力,進行研發項目的資金和資源的可獲得性,臨牀研究的成功和及時完成,泥盆紀公司利用製藥和化粧品行業商機的能力,與泥盆紀公司有關的不確定因素。在4月21日的泥盆紀招股説明書中,你會發現對可能導致實際事件或結果與我們目前預期有實質性差異的風險進行了更詳細的評估ST,2017年,標題為與泥盆紀業務相關的風險因素。因此,我們不能保證任何前瞻性聲明都會成為現實。我們不承擔更新任何前瞻性陳述的義務,除非適用的證券法律法規要求我們更新任何前瞻性陳述,即使由於未來事件或任何其他原因而獲得新信息也是如此。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所創業板政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
Dr André P. Boulet, PhD
President, Chief Executive Officer
Devonian Health Group inc.
Telephone: (514) 248-7509
Email: apboulet@groupedevonian.com
安德烈·P·布萊博士,博士總裁兼首席執行官泥盆紀健康集團有限公司。電話:(514)248-7509電子郵件:apboulet@groupedevonian.com